Dublin, OH-based Neoprobe announced that the University of California, San Diego (UCSD), recently received a European patent covering Lymphoseek.
Lymphoseek initially is being developed as a lymphatic tissue-targeting agent to improve the ability of physicians to indicate the spread of cancers such as breast cancer and melanoma.
Neoprobe holds the exclusive rights to Lymphoseek under license from UCSD for diagnostic use in applications such as lymphatic mapping, as well as in ultrasound and optical imaging.
By AuntMinnie.com staff writers
November 16, 2005
Related Reading
Neoprobe posts mixed Q3 results, November 4, 2005
Neoprobe Q2 sales up, but loss widens, August 2, 2005
Neoprobe inks new Lymphoseek deal, April 21, 2005
Neoprobe gets new Quantix/OR clearance, February 15, 2005
Neoprobe extends Japanese distribution deal, August 25, 2004
Copyright © 2005 AuntMinnie.com